Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kinetics of Red Blood Cell Clearance in Chronically Transfused Children With Sickle Cell Disease
NCT04426591Phase 1Completed
- Sponsor
- Marianne Yee Consulting
- Start
- Oct 2021
- Primary completion
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Biotinylated red blood cell in sickle cell disease (SCD) and thalassemia, sponsored by Marianne Yee Consulting. Primary endpoints: Percentage of Biotin Labeled RBCs at 90 days, Half-life of Biotinylated RBCs and 1 more. Started Oct 2021; status: completed.
02
Drugs
Biotinylated red blood cell
03
Conditions
sickle cell disease (SCD)thalassemia
Beyond the preview
Go deeper on NCT04426591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04426591.